Stockreport

Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]

Harrow Health, Inc.  (HROW) 
Last harrow health, inc. earnings: 11/13 04:21 pm Check Earnings Report
PDF Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in 2026, with potential for $2B+ by 2030. HROW's financials are accelerating: FCF/s [Read more]